论文部分内容阅读
目的 :检测肝门部胆管癌新鲜组织中多药耐药基因 (mdr - 1)mRNA表达 ,探讨其与肝门部胆管癌临床病理间的关系。方法 :应用逆转录多聚酶链反应 (RT PCR)对 2 6例术前未作治疗的肝门部胆管癌 ,12例正常胆管组织的mdr 1mRNA表达进行了检测 ,并与癌组织的分化程度、病理类型、部位、浸润转移作对比研究。结果 :2 6例肝门部胆管癌组织中mdr 1mRNA阳性表达率为 6 5 4% (17/ 2 6 ) ,正常胆管组织表达率为 8 3% (1/ 12 ) ,二者差异有显著性 (P <0 0 1)。mdr 1mRNA阳性表达与肝门部胆管癌的分化程度、发生部位、病理类型、浸润转移无关 (P >0 0 5 )。结论 :肝门部胆管癌组织中mdr 1mRNA的高表达可作为肝门部胆管癌化疗耐药的指标。
Objective : To detect the mRNA expression of multidrug resistance gene (mdr-1) in fresh tissue of hilar cholangiocarcinoma, and to explore the relationship between it and clinicopathology of hilar cholangiocarcinoma. Methods: RT-PCR was used to detect the expression of mdr 1 mRNA in 26 untreated hilar cholangiocarcinomas and 12 normal bile duct tissues. Type, location, infiltration and migration for comparative study. Results: The positive expression rate of mdr 1 mRNA in 26 cases of hilar cholangiocarcinoma was 65.4% (17/26), and the normal bile duct tissue expression rate was 83% (1/12). There was a significant difference between the two groups. (P < 0 0 1). The positive expression of mdr 1 mRNA was not related to the degree of differentiation, location, pathological type, invasion and metastasis of hilar cholangiocarcinoma (P > 0.05). Conclusion: The high expression of mdr 1 mRNA in hilar cholangiocarcinoma can be used as an indicator of chemotherapy resistance in hilar cholangiocarcinoma.